Earnings Data
Report Date
Aug 10, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.17Last Year’s EPS
-0.18Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed meaningful operational and commercial progress: record revenue (+12% YoY), double‑digit volume growth (+10% YoY), consistent ASP expansion (+6% YoY TTM) and improved adjusted EBITDA (14% improvement). The company also highlighted a growing pharma services backlog (> $5M), ongoing innovation (myositis target early 2027) and a healthy cash balance (~$22M). Offsetting risks include weather‑related volume loss in Q1, continued GAAP operating losses, reliance on lumpy prior‑period collections for ASP upside, an unresolved LCD timing risk, and the earlier loss of a client‑bill account. On balance the positives—organic growth, commercial momentum, ASP gains and pipeline advancement—outweigh the near‑term headwinds and uncertainties.Company Guidance
Record First Quarter Revenue and Year‑over‑Year Growth
Reported record Q1 revenue of $17.3 million, a 12% increase versus prior year, and management reaffirmed full‑year 2026 revenue guidance of $70.0M to $73.0M.
Test Volume Growth and Share Gains
AVISE CTD test volume grew 10% year‑over‑year, test volume remained in a mid‑30,000 quarterly run rate, and the company noted market growth of ~5% implying continued share gains from a current ~3% market share.
ASP Expansion and Revenue Cycle Wins
Trailing 12‑month ASP expanded to $444, up $25 or 6% year‑over‑year (12 consecutive quarters of TTM ASP increases). Quarter benefited from collection of over $900,000 in claims >360 days, which contributed roughly $25 to in‑period ASP.
Improvement in Profitability Metrics
Adjusted EBITDA loss narrowed to $2.2 million, a 14% improvement versus last year. Gross margin was 59% for Q1, up 360 basis points sequentially, with management targeting mid‑60s over time.
Commercial Momentum and Productivity
Ordering clinicians increased ~15% year‑over‑year to just over 2,700; trailing 12‑month volume per territory (sales productivity) improved ~4%; company expanded territory footprint and indicated continued ramp potential for newer reps.
Biopharma Services and Backlog Development
Pharma services generated roughly $300,000 of revenue in Q1 and the company reported a contract backlog of over $5 million expected to be realized over the next 2–3 years.
Pipeline Progress and Scientific Visibility
R&D advancing: next stand‑alone product (myositis) targeted for early 2027, 9 abstracts accepted at Autoimmunity 2026 and 2 manuscripts accepted for publication; new markers (PAD4, RA33) commercialized and already attracting pharma partnerships.
Liquidity Position
Cash, cash equivalents and restricted cash ended Q1 at just under $22 million, which management states provides runway toward sustainable positive free operating cash flow.
DE:E08A Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:E08A Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 11, 2026 | €2.46 | €2.90 | +17.89% |
Mar 10, 2026 | €2.76 | €2.86 | +3.62% |
Nov 04, 2025 | €9.95 | €10.00 | +0.50% |
Jul 29, 2025 | €6.10 | €6.25 | +2.46% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Exagen (DE:E08A) report earnings?
Exagen (DE:E08A) is schdueled to report earning on Aug 10, 2026, After Close (Confirmed).
What is Exagen (DE:E08A) earnings time?
Exagen (DE:E08A) earnings time is at Aug 10, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Exagen stock?
The P/E ratio of Exagen is N/A.
What is DE:E08A EPS forecast?
DE:E08A EPS forecast for the fiscal quarter 2026 (Q2) is -0.17.